Importantly, biomarker analysis in BC patients identified the combination of p4E-BP1T37/46 and p62 as a biomarker for poor survival, suggesting a potential utility in identifying a prognostically challenging subset of BC patients with mTORC1-mediated autophagy defects that may profit from metabolic therapies. Here, SQSTM1 is linked to breast cancer.